4536 Stock Overview
Engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 1/6 |
Financial Health | 6/6 |
Dividends | 5/6 |
Santen Pharmaceutical Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥1,876.50 |
52 Week High | JP¥1,875.00 |
52 Week Low | JP¥1,255.00 |
Beta | 0 |
11 Month Change | 3.79% |
3 Month Change | 15.26% |
1 Year Change | 38.23% |
33 Year Change | 9.99% |
5 Year Change | 4.66% |
Change since IPO | 506.63% |
Recent News & Updates
Recent updates
Santen Pharmaceutical Co., Ltd. Just Recorded A 25% EPS Beat: Here's What Analysts Are Forecasting Next
Aug 08Unpleasant Surprises Could Be In Store For Santen Pharmaceutical Co., Ltd.'s (TSE:4536) Shares
Jun 25Santen Pharmaceutical Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
May 11Is There An Opportunity With Santen Pharmaceutical Co., Ltd.'s (TSE:4536) 34% Undervaluation?
May 08Shareholder Returns
4536 | JP Pharmaceuticals | JP Market | |
---|---|---|---|
7D | 1.2% | 2.3% | 0.9% |
1Y | 38.2% | 20.9% | 13.7% |
Return vs Industry: 4536 exceeded the JP Pharmaceuticals industry which returned 20.9% over the past year.
Return vs Market: 4536 exceeded the JP Market which returned 13.7% over the past year.
Price Volatility
4536 volatility | |
---|---|
4536 Average Weekly Movement | 4.7% |
Pharmaceuticals Industry Average Movement | 4.9% |
Market Average Movement | 6.3% |
10% most volatile stocks in JP Market | 10.1% |
10% least volatile stocks in JP Market | 3.4% |
Stable Share Price: 4536 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4536's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1890 | 3,744 | Takeshi Ito | www.santen.com |
Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension. The company also offers sepetaprost, a prostaglandin analogue eye drop drug that is in phase 3 of clinical trials; and latanoprost, an ophthalmic emulsion of a prostaglandin F2a derivative which is filed for marketing approval for the treatment of glaucoma and ocular hypertension.
Santen Pharmaceutical Co., Ltd. Fundamentals Summary
4536 fundamental statistics | |
---|---|
Market cap | JP¥653.38b |
Earnings (TTM) | JP¥26.85b |
Revenue (TTM) | JP¥304.35b |
24.7x
P/E Ratio2.2x
P/S RatioIs 4536 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4536 income statement (TTM) | |
---|---|
Revenue | JP¥304.35b |
Cost of Revenue | JP¥125.24b |
Gross Profit | JP¥179.11b |
Other Expenses | JP¥152.26b |
Earnings | JP¥26.85b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 76.11 |
Gross Margin | 58.85% |
Net Profit Margin | 8.82% |
Debt/Equity Ratio | 0% |
How did 4536 perform over the long term?
See historical performance and comparisonDividends
1.8%
Current Dividend Yield45%
Payout RatioDoes 4536 pay a reliable dividends?
See 4536 dividend history and benchmarksSanten Pharmaceutical dividend dates | |
---|---|
Ex Dividend Date | Sep 27 2024 |
Dividend Pay Date | Dec 02 2024 |
Days until Ex dividend | 27 days |
Days until Dividend pay date | 93 days |
Does 4536 pay a reliable dividends?
See 4536 dividend history and benchmarks